ARCA biopharma establishes Special Committee to evaluate strategic options

Oruka Therapeutics, Inc.

Special Committee formed to explore options for maximizing stockholder value.
Committee includes Board Chairman Robert E. Conway (chair), Linda Grais, and Anders Hove.
Company believes multiple opportunities exist to enhance value, but no specific deal disclosed.
No timeline given for completion of strategic review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.